Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles
Molecular Therapy · 2025
DOI: 10.1016/j.ymthe.2025.07.014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025. Verfasst von Lasse Neukirch und 11 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Cooperation Unit "Applied Tumor Immunity", German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, Heidelberg, Germany. Hauptthemen laut MEDLINE: Dependovirus, Cancer Vaccines, CD4-Positive T-Lymphocytes, Antigens, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Personalized treatment has become a realistic option for tumor patients, accelerated by significantly reduced sequencing costs of tumor genomes and advances in vaccine formulations. The druggability of cancer neo-antigens caused by individual mutations is centered in this effort. We here use an adeno-associated virus (AAV)-based virus-like particle (VLP) platform to compose a neo-antigen-specific protein vaccine that is effective in a murine prevention and treatment setting. Furthermore, we show that CD4+ T cell responses that are provided by the AAV capsid are crucial for effective murine melanoma treatment. To uncover the optimal composition of a peptide vaccine we de-linked major histocompatibility complex (MHC) class II helper peptides from the capsid and formulated an efficient neo-antigen-specific vaccine, which showed the independence of CD4+ T cell response from tumor sequences. The findings are supported by clinical data of neo-antigen-vaccinated tumor patients. Our results punctuate on the significance of MHC class II epitopes for CD8+ T cell responses and suggest a future use of AAVLPs as neo-epitope vaccines in personalized cancer treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Cooperation Unit "Applied Tumor Immunity", German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, Heidelberg, Germany.
- Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Im Neuenheimer Feld 460, Heidelberg, Germany.
- GMP and T Cell Therapy Group, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.
- Clinical Cooperation Unit "Applied Tumor Immunity", German Cancer Research Center (DKFZ), Im Neuenheimer Feld 460, Heidelberg, Germany; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Universit…
- Department of Medical Oncology, National Center for Tumor Diseases (NCT), University Hospital Heidelberg, Im Neuenheimer Feld 460, Heidelberg, Germany; GMP and T Cell Therapy Group, German Cancer Research Center (DKFZ),…
Zitieren
APA
Neukirch, L., Uhrig-Schmidt, S., von Werthern, K., Tuch, A., Kraske, J. A., Lyu, Y., Lenoir, B., Eichmüller, S. B., Meyer, M., Zörnig, I., Jäger, D., & Schmidt, P. (2025). Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2025.07.014
Vancouver
Neukirch L, Uhrig-Schmidt S, von Werthern K, Tuch A, Kraske JA, Lyu Y, et al. Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles. Molecular Therapy. 2025. doi:10.1016/j.ymthe.2025.07.014
BibTeX
@article{Neukirch2025,
author = {Neukirch, Lasse and Uhrig-Schmidt, Silke and von Werthern, Katharina and Tuch, Alexandra and Kraske, Joscha A and Lyu, Yanhong and Lenoir, Benedicte and Eichmüller, Stefan B and Meyer, Marten and Zörnig, Inka and Jäger, Dirk and Schmidt, Patrick},
title = {Neo-antigen tumor vaccination depends on CD4-licensing conveyed by adeno-associated virus like particles},
journal = {Molecular Therapy},
year = {2025},
doi = {10.1016/j.ymthe.2025.07.014}
}
EUVIMED